Business
NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality
President Trump signed an Executive Order: ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS on April 18, 2026.The order directs acceleration of research and lowered barriers to approvals of psychedelic medications to treat depression, PTSD, and suicidality.NRx Pharmaceuticals has been awarded Fast Track designation and recently received FDA guidance anticipating NRx’s upcoming New Drug Application for NRX-100 (preservative free ketamine) to treat depression, including bipolar depressio
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"image","alt":"NRx Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"NRx Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/4ef53875d129fcc14f2614dd5795d5a9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oQlnKXAw77IR4.RQxkfHUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/4ef53875d129fcc14f2614dd5795d5a9","width":300,"height":300}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"President Trump signed an Executive Order: ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS on April 18, 2026.","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"The order directs acceleration of research and lowered barriers to approvals of psychedelic medications to treat depression, PTSD, and suicidality.","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"NRx Pharmaceuticals has been awarded Fast Track designation and recently received FDA guidance anticipating NRx’s upcoming New Drug Application for NRX-100 (preservative free ketamine) to treat depression, including bipolar depression, in patients who may have suicidal ideation.","length":279,"tagName":"p"}]},{"val":[{"type":"text","content":"Suicide remains the second leading cause of death among Americans under the age of 35 and the only currently-approved treatment for suicidality in depression remains Electroshock Therapy.","length":187,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":733,"olType":false},{"type":"text","content":"WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq:NRXP) welcomes the newly-signed Executive Order: ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS, signed by President Trump on April 18, 2026. In the Order, the President notes that, “It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America.”","length":509,"tagName":"p"},{"type":"text","content":"“We thank President Trump, Secretary Kennedy, and Commissioner Makary for their leadership and decisive action to address America’s mental health crisis, particularly the devastating to...